Navigation Links
New Blood Thinner Beats Older Drug for Vein Clots: Study
Date:2/20/2013

By Steven Reinberg
HealthDay Reporter

WEDNESDAY, Feb. 20 (HealthDay News) -- People who need to take a blood thinner because they've had a clot in the deep veins of their legs appear to do better with the new drug Pradaxa (dibigatran) than with the older drug warfarin, researchers report.

Long-term treatment of these blood clots is safer and more convenient with Pradaxa than warfarin, the new study found.

Extended treatment with blood thinners after clots develop in the veins or the lungs should be considered more often than it is, said lead researcher Dr. Sam Schulman, a professor in the division of hematology and thromboembolism at McMaster University in Hamilton, Ontario, Canada.

If a clot in the leg breaks loose and travels to the heart, brain or lungs, it can cause a heart attack, stroke or a pulmonary embolism -- all of which can be fatal.

People taking warfarin need periodic blood tests to be sure they aren't getting too much of the drug, which raises the risk of major bleeding, or too little, which is ineffective.

Pradaxa also has a lower risk of bleeding than warfarin, Schulman said, and the bleeding that does occur is less serious than that seen with warfarin, he added.

For the study, published Feb. 21 in the New England Journal of Medicine, Schulman's team conducted two studies of more than 2,800 patients, average age 56, who had clots in the legs, also known as venous thromboembolism. In one, Pradaxa was compared with warfarin, and in the other Pradaxa was compared with placebo.

In the Pradaxa-warfarin comparison, the researchers found that 1.8 percent of patients taking Pradaxa had recurrent clots, compared with 1.3 percent of patients taking warfarin. Fewer patients taking Pradaxa, however, had major bleeding (13) compared with those taking warfarin (25).

In the study comparing Pradaxa with a placebo, three patients taking the drug developed clots, compared with 37 patients taking placebo.

In this group, two patients taking Pradaxa developed major bleeding, while none in the placebo group did, the researchers added.

The trials were paid for by Boehringer Ingelheim, the maker of Pradaxa.

"These new anticoagulants are great and appear to be as effective as the only other oral one out there, warfarin," said Dr. Jean Connors, medical director of the anticoagulation management service at Brigham and Women's Hospital and Dana-Farber Cancer Institute in Boston.

They do, however, still have the risk of bleeding associated with them, said Connors, who wrote an accompanying journal editorial. "But they are easier to take because you don't need blood tests," she said.

Antidotes to bleeding caused by Pradaxa are in the works, Connors said. "With warfarin, bleeding can be reversed within half an hour, whereas with these drugs there is no good specific reversal for them," she said.

Cost of treatment is a consideration, too. Although Pradaxa is a lot more expensive than warfarin up front, when the associated costs of monitoring are accounted for, the two drugs appear to run about the same, Connors said.

"Warfarin is an extremely cheap drug, costing anywhere from $5 to $10 a month, and co-pays for Pradaxa are anywhere from $25 to $50 a month," she said.

Some cautions may be in order, however. Recently, the U.S. Food and Drug Administration said in a warning that Pradaxa should not be used to prevent stroke or blood clots in patients with mechanical heart valves.

The agency noted that a clinical trial in Europe was halted because patients taking Pradaxa were more likely to suffer strokes, heart attacks and clots forming on their mechanical heart valves than patients taking warfarin.

More information

For more information on deep venous thrombosis, visit the U.S. National Library of Medicine.

SOURCES: Sam Schulman, M.D., Ph.D., professor, Division of Hematology and Thromboembolism, McMaster University, Hamilton, Ontario, Canada; Jean Connors, M.D., medical director, Anticoagulation Management Service, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston; Feb. 21, 2013, New England Journal of Medicine


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Children’s Cancer & Blood Foundation to Host Private Party at American Girl Place, New York City
2. Damage to Tiny Blood Vessels in Brain May Raise Alzheimers Risk
3. NuvaRing Lawsuit Filed on Behalf of a South Carolina Woman who Developed Two Blood Clots While Using NuvaRing, Reports Wright & Schulte LLC
4. US Drug Watchdog Now Urges All DePuy ASR And Pinnacle All Metal Hip Implant Recipients To Get A Blood Test And To Call Them Before The Time Runs Out To Get Identified
5. STEMSOFT and The Canadian Blood and Marrow Transplant Group Announce Partnership
6. High Blood Pressure in Pregnancy May Predict Later Ills, Study Says
7. NuvaRing Blood-Clotting Victims Still Eligible to File Lawsuits Through Resource4thePeople
8. Blood-based test detects cancer earlier, from the February 2013 Harvard Health Letter
9. Scientists discover protein that allows safe recycling of iron from old red blood cells
10. US Drug Watchdog Now Urges All DePuy ASR and Pinnacle Hip Implant Recipients to Get a Blood Test for Metals Levels and to Call Them for the Names of the Best Law Firms
11. Rock River Valley Blood Center offering Pint of Culver’s Frozen Custard to Donors in February
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Blood Thinner Beats Older Drug for Vein Clots: Study
(Date:8/22/2017)... ... ... Walk Away”: a captivating and romantic sequel to the romantic story of a ... creation of published author, Larry R. Sherman, a retired chemistry professor from the University ... well as four novels. , Though the book opens in 1947, when Edward ...
(Date:8/22/2017)... ... ... “Glimpses Of Light”: is a unique and thought inspiring guide toward self-discovery and ... author, J.M. Shepherd, a writer, teacher, traveler, and metaphysician, the author has spent most ... “Love is one of the least understood and yet most sought-after pleasures known to ...
(Date:8/22/2017)... (PRWEB) , ... August 22, 2017 , ... Although Labor ... of July, many communities have begun providing weekend displays, and numerous households celebrate the ... humans, they can be downright terrifying for pets. , Kris Zambo, owner of ...
(Date:8/21/2017)... ... 21, 2017 , ... Los Angeles area medical group Beverly ... year 2017-2018, Christina M. Busuito, M.D. and Lukasz Swistun, M.D. This one year ... Reconstructive Surgery. The candidate will have the opportunity to work with leading ...
(Date:8/21/2017)... ... 2017 , ... Marathon running has surged in popularity in ... running increases exposure to ultraviolet radiation, a carcinogen that promotes skin cancer. Studies ... half may be adequately protecting themselves with proper clothing and sunscreen. , ...
Breaking Medicine News(10 mins):
(Date:8/4/2017)... Aug. 3, 2017  Agragen, LLC, a ... in the biopharmaceutical, nutraceutical, and aquacultural feed sectors, ... its lead drug candidates, AGR131.  This drug is ... from the blood of patients suffering from inflammatory ... bowel disease. ...
(Date:8/2/2017)... Aug. 2, 2017 CaryRx, a next-generation full-service pharmacy, ... service for patients in the Washington D.C. ... pharmacy by providing delivery of medications through the convenience of ... delivery or delivered within one hour to any location in ... to bring this invaluable service to Washington D.C. ...
(Date:7/28/2017)... 2017 Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), ... ended June 30, 2017, and updated its financial outlook ... For the fiscal third quarter, Hill-Rom reported earnings ... diluted share in the prior-year period. These results reflect ... diluted share primarily related to the non-cash write-down of ...
Breaking Medicine Technology: